9 5 7 4 9
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
贝伐珠单抗 (Bevacizumab) 联合紫杉醇 (paclitaxel) 脂质体+顺铂 (cisplatin) 治疗鼻咽癌 1 例并文献复习
Authors He W, Zou C, Tian ZK, Tan WY, Shen WX, Chen JH, Liu LP, Xu RL
Received 13 September 2016
Accepted for publication 29 October 2016
Published 20 December 2016 Volume 2017:10 Pages 67—72
DOI https://doi.org/10.2147/OTT.S122238
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ashok Kumar Pandurangan
Peer reviewer comments 2
Editor who approved publication: Dr Samir Farghaly
摘要：鼻咽癌 IV 期患者即使进行有效化疗预后仍差。靶向联合化疗可改善鼻咽癌患者预后。现报道 1 例鼻咽癌患者一线化疗病情进展后加用贝伐珠单抗的临床资料；检索近年来国内外发表的有关贝伐珠单抗联合化疗应用于鼻咽癌细胞株或患者的文献并进行讨论。与现有数量有限的临床前试验和 II 期临床试验相一致，贝伐珠单抗可逆转化疗药物耐药性，毒副反应可控。
关键词：鼻咽癌，贝伐珠单抗，耐药性，联合治疗
